Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer
Journal
Journal of Controlled Release
Journal Volume
324
Pages
482-492
Date Issued
2020
Author(s)
SDGs
Other Subjects
Amino acids; Biological organs; Cell signaling; Drug products; Enzyme inhibition; Acquired resistance; Clinical efficacy; Efficient treatment; Epidermal growth factor receptors; Non small cell lung cancer; Sustained release; Therapeutic outcomes; Tyrosine kinase inhibitor; Diseases; antineoplastic agent; epidermal growth factor receptor; lactic acid; nanocarrier; nucleic acid; plasmid DNA; protein tyrosine kinase inhibitor; virus vector; EGFR protein, human; epidermal growth factor receptor; protein kinase inhibitor; cancer immunotherapy; cancer resistance; cytoreductive surgery; DNA transfection; drug formulation; gene mutation; human; in vitro study; in vivo study; metastasis; nanopharmaceutics; nanotechnology; non small cell lung cancer; nonhuman; oncolytic virotherapy; priority journal; Review; RNAi therapeutics; sustained drug release; treatment outcome; tumor microenvironment; drug resistance; genetics; lung tumor; mutation; non small cell lung cancer; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors
Publisher
Elsevier B.V.
Type
review